Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Voiceline II speaking valve (green)
20050600170
|
Voiceline II speaking valve (green) | Tracheostomy & Laryngectomy Appliances | Dressings | No data available |
|
Voiceline II speaking valve (orange)
20050600171
|
Voiceline II speaking valve (orange) | Tracheostomy & Laryngectomy Appliances | Dressings | No data available |
|
Voiceline II speaking valve (pink)
20050600172
|
Voiceline II speaking valve (pink) | Tracheostomy & Laryngectomy Appliances | Dressings | No data available |
|
Voiceline II speaking valve (white)
20050600169
|
Voiceline II speaking valve (white) | Tracheostomy & Laryngectomy Appliances | Dressings | No data available |
|
Voleze 13.3mg/24hours transdermal patches
0411000E0BEACAI
|
Voleze | Rivastigmine | Central Nervous System | No data available |
|
Voleze 4.6mg/24hours transdermal patches
0411000E0BEAAAF
|
Voleze | Rivastigmine | Central Nervous System | No data available |
|
Voleze 9.5mg/24hours transdermal patches
0411000E0BEABAG
|
Voleze | Rivastigmine | Central Nervous System | No data available |
|
Volibris 10mg tablets
0205010X0BBABAB
|
Volibris | Ambrisentan | Cardiovascular System | No data available |
|
Volibris 2.5mg tablets
0205010X0BBACAC
|
Volibris | Ambrisentan | Cardiovascular System | No data available |
|
Volibris 5mg tablets
0205010X0BBAAAA
|
Volibris | Ambrisentan | Cardiovascular System | No data available |
|
Volmax 4mg modified-release tablets
0301011R0BNAABE
|
Volmax | Salbutamol | Respiratory System | No data available |
|
Volmax 8mg modified-release tablets
0301011R0BNABBF
|
Volmax | Salbutamol | Respiratory System | No data available |
|
Volplex 4% infusion 1litre bags
0902022I0BDABAC
|
Volplex | Gelatin | Nutrition and Blood | No data available |
|
Volplex 4% infusion 500ml bags
0902022I0BDAAAA
|
Volplex | Gelatin | Nutrition and Blood | No data available |
|
Volraman 25mg gastro-resistant tablets
1001010C0BFAAAD
|
Volraman | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volraman 50mg gastro-resistant tablets
1001010C0BFABAE
|
Volraman | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volsaid Retard 100 tablets
1001010C0BSABAF
|
Volsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volsaid Retard 75 tablets
1001010C0BSAAAL
|
Volsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 25mg gastro-resistant tablets
1001010C0BBAAAD
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 50mg dispersible tablets
1001010C0BBAGAJ
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 50mg gastro-resistant tablets
1001010C0BBABAE
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 75mg SR tablets
1001010C0BBAHAL
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Active 4% spray
1003020U0BIAAAH
|
Voltarol Active | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Joint Pain 12.5mg tablets
1001010AGBDAAAC
|
Voltarol Joint Pain | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Pain-eze 12.5mg tablets
1001010AGBCAAAC
|
Voltarol Pain-eze | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.